☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - April 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Emtricitabine / Tenofovir (Truvada®) has been accepted for use in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. It should denoted that NHS Boards in Scotland will make it available within the next three months when systems are in place.

Insulin aspart (Fiasp®) has been accepted for the treatment of diabetes mellitus in adults. It is noted that this is a new formulation with a faster onset of action than another formulation of insulin aspart and is available at an equivalent cost.

Ticagrelor (Brilique®) has been rejected for use when co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event. The manufacturer did not present a sufficiently robust clinical and economic analysis to gain acceptance.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - April 2017' on Email Share 'SMC Update - April 2017' on Delicious Share 'SMC Update - April 2017' on Digg Share 'SMC Update - April 2017' on Facebook Share 'SMC Update - April 2017' on reddit Share 'SMC Update - April 2017' on Twitter


No Comments to “SMC Update - April 2017”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.